secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2026-08-13T20:06:44+00:00
Accession:  0001193125-26-349160
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT Q2 net loss $72.9M; 4D-150 Phase 3 enrollment complete, $200M credit facility
--------------------------------------------------------------------------------

- Net loss $72.9M vs $54.7M; R&D expenses $68.3M vs $48.0M; G&A $12.5M vs $11.5M.
- Cash $430.6M at June 30, 2026, down from $514.0M; funds into H2 2028.
- 4D-150 4FRONT-1 topline Q2 2027 (N=523); 4FRONT-2 enrollment complete, topline H2 2027.
- PRISM 2-yr data: 78% treatment burden reduction overall, 87% in recently diagnosed; no new inflammation.
- $200M Hercules credit facility, initial draw $20M; DME Phase 3 to start Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/0001193125-26-349160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer